2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MPN, CML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

1964 TGF-β  signaling pathway regulates clonal expansion of Jak2V617F  hematopoietic stem/progenitor cells

Jun Xia, PhD, Elaheh Nasrollahzadeh, MD2, Juo-Chin Yao3, Iris Yang4, Kartik Singhal5, Malachi Griffith, PhD6, Daniel Gai7, Daniel C. Link, MD8
1 Washington University in St.Louis, St.Louis, Missouri, United States
2 Washington University in St.Louis, St.Louis, Missouri, United States
3 Washington University in St.Louis, St.Louis, Missouri, United States
4 Washington University in St.Louis, St.Louis, Missouri, United States
5 Washington University in St.Louis, St.Louis, Missouri, United States
6 Washington University in St.Louis, St.Louis, Missouri, United States
7 Washington University in St.Louis, St.Louis, Missouri, United States
8 Washington University in St.Louis, St.Louis, United States

Gain-of-function mutations in tyrosine kinase signaling genes, such as FLT3, KIT, NRAS, or KRAS, are relatively common in myeloid malignancies. In contrast, they are relatively infrequent in clonal hematopoiesis (CH), suggesting that their expression in HSCs (at least in the absence of cooperating mutations) does not confer a fitness advantage. A major exception to this observation is JAK2. The frequency of JAK2 CH based on UK Biobank data is 0.71% (324 of 454,840) compared with 0.02% for FLT3, 0.03% for KIT, 0.06% for NRAS, and 0.17% for KRAS (Fisher’s exact test:  <0.0001 for all comparisons to JAK2). These data suggest that JAK2 mutations may have unique properties conferring a fitness advantage to HSCs and contributing to the development of myeloproliferative neoplasms. Prior studies showed that TGF-β expression is increased in most cases of MPN. This is relevant, since TGF-β signaling has been implicated in the regulation of HSC quiescence and repopulating activity. We previously reported results of a series of competitive transplantation experiments in which TGF-β signaling was genetically ablated in wildtype HSPCs, JAK2V617F HSPCs, or both. These data show that loss of TGF-β signaling in wildtype competitor HSPCs abrogates the clonal expansion of JAK2V617F HSPCs over time. Here, we explore mechanisms by which TGF-β signaling confers a fitness advantage to JAK2V617F HSCs.

We first explored the possibility that Jak2V617F attenuates canonical TGF-β signaling in HSCs. Freshly isolated bone marrow cells from wildtype or Jak2V617F mice were stimulated in vitro with 10 ng/ml of TGF-β for 30 minutes and then assessed for pSAMD2/3 by flow cytometry. Interestingly, TGF-β-induced SMAD2/3 phosphorylation was selectively inhibited in Jak2V617F HSCs but not committed myeloid progenitors. Similar data were observed with human MPN samples, where mass cytometry showed reduced TGF-β-induced SMAD2/3 phosphorylation in CD34+ CD38- Jak2V617F cells.  However, if we cultured wildtype or Jak2V617F bone marrow cells overnight, TGF-β-induced SMAD2/3 phosphorylation was similar. These observations suggested that the constitutive high level of TGF-β in the bone marrow of Jak2V617F mice may result in TGF-β receptor internalization and reduced signaling. To test this possibility, we generated mixed bone marrow chimeras containing wildtype and Jak2V617F HSPCs. Indeed, we show that TGF-β-induced SMAD2/3 phosphorylation is similar in wild type and Jak2V617F HSCs when exposed to the same level of TGF-β in vivo. Thus, we conclude that TGF-β-induced canonically signaling is not altered in Jak2V617F HSCs.

TGF-β is a major regulator of HSC proliferation, a key determinant of HSC fitness. Thus, we next assessed the impact of the presence of Jak2V617F on HSC cell cycle status. We again established mixed bone marrow chimeras contain similar percentages of wildtype and Jak2V617F HSCs.  Flow-based cell cycle analysis and Edu incorporation showed that Jak2V617F HSC are less quiescent than wildtype HSC. To examine the role of elevated TGF-β present in these mice on HSC cell cycle, we treated mixed bone marrow chimeras with SM16, a potent and specific TGF-β inhibitor. Of note, we confirmed that treatment with SM16 efficiently suppresses TGF-β induced SMAD2/3 phosphorylation in HSPCs.  We show that suppression of TGF-β signaling leads to increased Edu corporation in both wildtype and Jak2V617F HSCs but the response is attenuated in Jak2V617F HSC (1.7-fold vs 2.3-fold in WT).  CDKN1A (p21), CDKN1B (p27) and CDKN1C (p57) are important regulators of HSC quiescence, with p57 being a known TGF-β target gene. Indeed, we show that treatment with high dose TGF-β in vivo results in a significant decrease in p57 expression in both wildtype and Jak2V617F HSCs. We next examined p57 mRNA expression under more physiological TGF-β levels using the Jak2V617F mixed bone marrow chimeras.  We performed single cell RNA sequencing on KLS cells sorted from mixed bone marrow chimeras containing GFP-tagged wildtype and Jak2V617F HSPCs, using GFP expression to identify wildtype cells.  Under these conditions, expression of p57 (or p21/p27) is similar in wildtype and Jak2V617F HSCs. 

In summary, our data show that Jak2V617F HSCs gain a fitness advantage in a non-cell intrinsic fashion by increasing TGF-β expression in the bone marrow microenvironment. Preliminary data suggest that TGF-β-induced regulation of HSC quiescence may contribute to the fitness advantage of Jak2V617F HSCs. 

Jun Xia, PhD: No relevant conflicts of interest to declare.